Sarepta Therapeutics, Inc.
ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN

Abstract:

The present disclosure relates to antisense oligomers and related compositions and methods for decreasing the expression of functional human myostatin and methods for treating muscular dystrophy and related disorders and more specifically relates to inducing exclusion of myostatin exon 2 and thereby reducing levels of myostatin protein.